UCB deal gives Roche a second shot on goal with tau in Alzheimer’s

Roche’s addition of UCB’s anti-tau mAb to its portfolio suggests the pharma’s strategy for the latest big Alzheimer’s target may be taking a path similar to its amyloid-based pursuit.

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit will gain exclusive, global rights to UCB0107 in exchange for $120 million up front; and up to nearly $2 billion in cost reimbursements, milestones and royalties. ...